Paula Klein, MD
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
- Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Beth Israel
- Mount Sinai St. Luke's and Mount Sinai West
One hundred percent (100%) of my clinical practice is devoted to medical oncology care for breast cancer patients from all parts of the Tri-State area. It includes both male and female patients as well as all stages of breast cancer from DCIS through advanced disease, where my particularl interest lies. It includes chemoprevention strategies for many who have not been diagnosed with invasive disease but are at high risk making them appropriate for prevention. I see many premenopausal patients as well as the more common postmenopausal patients hoping to offer almost every patient an opportunity to enroll in a clinical trial, either with a new therapy (targeting patient’s unique tumor type and biology) or a new drug or drug combinations including biologics. I also encourage participation in integrative medicine such as YOGA to relax early stage breast cancer patients receiving adjuvant chemotherapy as well acupuncture for treatment related toxicities such as neuropathy and anxiety.
I am proud to serve as the Chief Medical Officer of the Marisa Acocella Marchetto Foundation, a foundation dedicated to EMPOWER uninsured and underinsured women with breast cancer and breast cancer survivors to receive the best possible care without being concerned about the financial ramifications. Services from screenings to holistic care to the newest methods of empowerment are funded.
I am currently serving as the President of the New York Metropolitan Breast Cancer Group, a multidisciplinary group of all relevant specialties, including radiology, surgical oncology, medical oncology and radiation oncology dedicated to an exchange of ideas through education and cooperation focused on the treatment of breast cancer patients in the New York Metropolitan area. We are a medical society that shares a common interest in promoting and improving the quality of breast cancer care
I serve on the Breast Disease Management Team at Mount Sinai developing standards of care and clinical pathways across the system to ensure evidence based practice with attention to quality of life for all patients diagnosed with breast cancer and treated anywhere in the health system.
I also serve on the Breast Disease Focus Group to bring forward new clinical trials, industry sponsored as well as cooperative group and investigator initiated, to enhance the care of our breast cancer patients and serve to move the field as forward as we can.
American Board of Internal Medicine
MD, SUNY Downstate Medical Center - College of Medicine
Residency, Internal Medicine
New York University School of Medicine
Fellowship, Hematology Oncology
Bellevue Hospital Center
Best Doctors-New York Magazine
Best Doctors-New York Magazine
Best Doctors-New York Magazine
RUBYFRUIT recognition of outstanding work and dedication in BREAST ONCOLOGY
U.S. Army Corps of Engineers, Commander’s Certificate of Appreciation
Amgen Oncology Fellowship Program at New York University Medical Center
Alpha Omega Alpha Honor Society
Klein P, McMeeking A, and Goldenberg A. Babesiosis in a patient with sickle-cell anemia. Am J Med. 102(4): 416, 1997..;.
Klein P, Muggia F. Cytoprotection: Shelter from the storm. Helix. VII (3): 48-56, 1998..;.
Klein P, Muggia FM. Cytoprotection: Shelter from the storm. The Oncologist. 4(2): 112-121, 1999..;.
Klein P, Prolla G, Wallach R, Melamed J, Muggia FM. BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary. Cancer J. Sci Am. 6(3):188-90, 2000..;.
Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S. Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res. 8(12)4610-7, 2000..;.
Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L. Phase II trial of weekly vinorelbine and trastuzumab as first line therapy in patients with HER2+ metastatic breast cancer. The Oncologist. 7(5): 410-417, 2002..;.
Heiba SI, Bernik S, Raphael B, Sandella N, Cholewinski W, Klein P. The distinctive role of positron emission tomography/computed tomography in breast carcinoma with brown adipose tissue 2-fluoro-deoxy-d-glucose uptake. Breast Journal 11(6):457-61, 2005..;.
Taylor L, Aziz M, Klein P, Mazumder A, Jagannath S, Axelrod D. Plasmacytoma in the breast with axillary lymph node involvement: a case report. Clinical Breast Cancer 7(1):81-4, 2006..;.
Abdel-Dayem HM, Sadek S, Steinmetz N, Cho J, Klein P, Nuclear Medicine Department, St. Vincent’s Catholic Medical Centers of New York, New York, USA, Thesus Imaging Corporation, Boston USA, St. Vincent’s Comprehensive Cancer Center, New York USA. 99mTc rh-Annexin V for Imaging Apoptotic Cells: Clinical Experience (in press).;.
Chockalingam P, Astrow AB, Klein P, Huang Y, Reichman BS, Citron ML. Isolated Sternal Recurrence In Breast Cancer, Is It Truly Stage 4 Disease. Clinical Breast Cancer, Vol. 11,(3):191-194, 2011 .;.
Ellen Chuang, Paul Christos, Arielle Flam, Katherine McCarville, Melissa Forst, Sandra Shin, Linda Vahdat, Alexander Swistel, Rache Simmons and Michael Osborne, Mazumder M, Paula Klein. Breast Cancer Subtypes in Asian-Americans Differ According to Asian Ethnic Group JOURNAL OF IMMIGRANT AND MINORITY HEALTH DOI: 10.1007/s10903-012-9577.;.
T Shao, M Grossbard, P Klein. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer. 2011 Dec;11(6):417-9. Epub 2011 Aug .;.
S Lewin, D Dezube, AK Guddati, K Mittal, F Muggia and Paula Klein. Paraneoplastic hypercalcemia in clear cell ovarian adenocarcarcinoma. Ecancer 2012, 6:271 DOI: 10.3332/eancer.2012271.;.
GS Schwartz, D Antoun, P Klein, SJ Belsley, CP Connery. Internal Mammary silicone lymphadenopathy by robotic thoracoscopic lymphadenectomy. J of Robotic Surg DOI 10.1007/s1170-012-0368-x.;.
AJ Olszewski, Y Migdady, SK Boolbol, P Klein, K Boachie-Adjei, BJ Sakr, W Sikov, T Shao Effects of adjuvant chemotherapy in HER2 positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. Breast Cancer Research and Treatment January .;.
D Hyams, A Chan, C de Oliveira, R Snyder, J Vinholes, M Audeh, V Alencar, J Lombard, B Mookerjee, J Xu, K Brown, P Klein. Cedarinib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: Investigational New Drugs 10.1007/s10637-013-9991-2, June 2013.;.
Alsabbak H, Aljuboori Z, Spierer M, Klein P (2013) The Association of Adjuvant Trastuzumab (Herceptin) with Radiation Recall Dermatitis: A Case Study. J Cancer Sci Ther 5:427-429. doi: 10.4172/1948-5956.1000236.;.
Chandana Kakani, Isabel Ruth Preeshagul, Rebecca Fisher, Paula Klein. Management of isolated leptomeningeal metastasis as the initial and sole site of recurrence in a patient with early-stage breast cancer: International Cancer Conference Journal: April, 2015 Volume 4, Issue 2 (2015), Page 101-104.;.
Kerin B. Adelson, MD1, Bhuvaneswari Ramaswamy2, MD, Joseph A. Sparano, MD3, Paul J. Christos, DrPH, MPH4, John J. Wright, MD, PhD5, George Raptis, MD, MBA6, Gang Han, PhD1, Miguel Villalona2, Cynthia X. Ma, MD7, Dawn Hershman, MD, MS8, Joseph Baar, MD9, Paula Klein, MD10, Tessa Cigler, MD, MPH4, Thomas Budd, MD11, Yelena Novik, MD12, Antoinette R. Tan, MD13, Susan Tannenbaum, MD14, Anupama Goel, MD15, Ellis Levine, MD16, Charles L. Shapiro, MD2, Eleni Andreopoulou, MD3, Michael Naughton, MD7, Kevin Kalinsky, MD, MS8, Sam Waxman, MD17, Doris Germain, PhD17 Randomized Phase II Trial of Fulvestrant Alone.;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Klein did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.